Patents by Inventor Alejandro Dorenbaum

Alejandro Dorenbaum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of PPAR-delta agonists in the treatment of disease
    Patent number: 11931365
    Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR? agonist compound.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: March 19, 2024
    Assignee: RENEO PHARMACEUTICALS, INC.
    Inventors: Niall O′Donnell, Lynn Purkins, Alejandro Dorenbaum
  • Methods for treating cholestasis
    Patent number: 11918578
    Abstract: Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 ?g/kg/day.
    Type: Grant
    Filed: October 5, 2022
    Date of Patent: March 5, 2024
    Assignee: MIRUM PHARMACEUTICALS, INC.
    Inventors: Thomas Jaecklin, Alejandro Dorenbaum
  • USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE
    Publication number: 20240016809
    Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR? agonist compound.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 18, 2024
    Inventors: Niall O'DONNELL, Lynn PURKINS, Alejandro DORENBAUM
  • USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE
    Publication number: 20230233570
    Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR? agonist compound.
    Type: Application
    Filed: January 25, 2023
    Publication date: July 27, 2023
    Inventors: Niall O'DONNELL, Lynn PURKINS, Alejandro DORENBAUM
  • METHODS FOR TREATING CHOLESTASIS
    Publication number: 20230190742
    Abstract: Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 µg/kg/day.
    Type: Application
    Filed: October 5, 2022
    Publication date: June 22, 2023
    Applicant: Mirum Pharmaceuticals, inc.
    Inventors: Thomas JAECKLIN, Alejandro DORENBAUM
  • Methods for treating cholestasis
    Patent number: 11497745
    Abstract: Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 ?g/kg/day.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: November 15, 2022
    Assignee: MIRUM PHARMACEUTICALS, INC.
    Inventors: Thomas Jaecklin, Alejandro Dorenbaum
  • METHODS FOR TREATING CHOLESTASIS
    Publication number: 20220160726
    Abstract: Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 ?g/kg/day.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 26, 2022
    Applicant: MIRUM PHARMACEUTICALS, INC.
    Inventors: Thomas JAECKLIN, Alejandro DORENBAUM
  • METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE
    Publication number: 20220152022
    Abstract: Provided herein are methods for increasing growth in a pediatric subject having a cholestatic liver disease. The method includes administering to the subject an effective amount of an ASBTI.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 19, 2022
    Applicant: MIRUM PHARMACEUTICALS, INC.
    Inventors: Thomas JAECKLIN, Alejandro DORENBAUM
  • GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY
    Publication number: 20220133738
    Abstract: Provided herein are methods for treating or ameliorating cholestatic liver disease in a subject in need thereof. The methods include administering an Apical Sodium-dependent Bile Acid Transport Inhibitor (ASBTI) to the subject. The methods include determining a genotype of the subject and predicting subject response to the ASBTI administration based upon the genotype. The methods further include determining, adjusting, or modulating a dose of the ASBTI administered to the subject based upon the genotype or upon measurements of clinically relevant disease parameters.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 5, 2022
    Applicant: MIRUM PHARMACEUTICALS, INC.
    Inventors: Thomas JAECKLIN, Alejandro DORENBAUM
  • METHODS FOR TREATING CHOLESTASIS
    Publication number: 20220105092
    Abstract: Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 ?g/kg/day.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Applicant: Mirum Pharmaceuticals, Inc.
    Inventors: Thomas Jaecklin, Alejandro Dorenbaum
  • Methods for treating cholestasis
    Patent number: 11229647
    Abstract: Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 ?g/kg/day.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: January 25, 2022
    Assignee: MIRUM PHARMACEUTICALS, INC.
    Inventors: Thomas Jaecklin, Alejandro Dorenbaum
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS
    Publication number: 20180256582
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • Methods and compositions for the treatment of metabolic disorders
    Patent number: 9993481
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: June 12, 2018
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING
    Publication number: 20170000793
    Abstract: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.
    Type: Application
    Filed: April 6, 2016
    Publication date: January 5, 2017
    Inventors: Daniel I. Oppenheimer, Alejandro Dorenbaum, Augustus O. Okhamafe, Erik Foehr, Sianna Castillo, Paul John Kostel
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS
    Publication number: 20160367558
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • Methods and compositions for the treatment of metabolic disorders
    Patent number: 9433624
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: September 6, 2016
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING
    Publication number: 20130237543
    Abstract: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.
    Type: Application
    Filed: February 6, 2013
    Publication date: September 12, 2013
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel I. Oppenheimer, Alejandro Dorenbaum, Augustus O. Okhamafe, Erik Foehr, Sianna Castillo, Paul John Kostel
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS
    Publication number: 20120108599
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Application
    Filed: November 16, 2011
    Publication date: May 3, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • Methods and compositions for the treatment of metabolic disorders
    Patent number: 8067416
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: November 29, 2011
    Assignees: Merck Eprova AG, Biomarin Pharmaceutical Inc.
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • Methods of administering tetrahydrobiopterin
    Patent number: RE43797
    Abstract: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: November 6, 2012
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Daniel I. Oppenheimer, Alejandro Dorenbaum, Augustus O. Okhamafe